Up-to-date experience with the international classification system Bethesda 2010 for thyroid fine-needle aspirate: a review
Authors:
Marie Ludvíková 1,2; Ivana Kholová 3
Authors place of work:
Ústav biologie LF UK Plzeň
1; Ústav patologie 1. LF UK a VFN Praha
2; Patologie, Fimlab Laboratoře, Univerzitní nemocnice v Tampere, Tampere, Finsko
3
Published in the journal:
Čes.-slov. Patol., 50, 2014, No. 3, p. 155-160
Category:
Reviews Article
Summary
The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) was introduced in thyroid fine needle aspiration cytology (FNAC) in 2010. A six-tier system is generally accepted. Bethesda categories include morphologic description, risk of malignancy and follow-up suggestions in each group. The system has its advantages and disadvantages, that are discussed. The most problematic are the categories of „Atypia of undetermined significance“ or „Follicular lesion of undetermined significance“ (AUS/FLUS). The group is heterogenous and overused thus far. The possibilities of its improvement are discussed. The Bethesda system does not include any prognostic and predictive markers. However, they represent the promising direction in the improved version of the BSRTC. Novel molecular methods and alternative techniques such as core needle biopsy are briefly discussed.
Keywords:
fine needle aspiration cytology – thyroid gland – Bethesda classification 2010 – benefits - shortcomings
Zdroje
1. Čáp J, Ryška A. Aspirační cytologie štítné žlázy. NUCLEUS HK; 2003: 31-36; 86-102.
2. Fonseca E, Sobrinho-Simoes M. Diagnostic problems in differentiated carcinomas of the thyroid. Pathol Res Pract 1995; 191(4): 318-331.
3. Poller DN, Ibrahim AK, Cummings MH, Mikel JJ, Boote D, Perry M. Fine-needle aspiration of the thyroid. Cancer 2000; 90(4): 239-244.
4. Yoder BJ, Redman R, Massoll NA. Validation of a five-tier cytodiagnostic system for thyroid fine needle aspiration biopsies using cytohistologic correlation. Thyroid 2006; 16: 781-786.
5. Bongiovanni M, Krane JF, Cibas ES, Faquin WC. The atypical thyroid fine-needle aspiration: past, present, and future. Cancer Cytopathol 2012; 120(2): 73-86.
6. Guidelines of the Papanicolaou Society of Cytopathology for fine-needle aspiration procedure and reporting. The Papanicolaou society of cytopathology task force on standards of practice. Diagn Cytopathol 1997; 17: 239-247.
7. Cooper DS, Doherty GM, Haugen BR, et al. American Thyroid Association Guidelines Taskforce. Management guidelines for patiens with thyroid nodules and differentiated cancer. Thyroid 2006; 16(2): 109-142.
8. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of Science Conference. Diagn Cytopathol 2008; 36: 425-437.
9. Kocjan G, Cochand-Priollet B, de Agustin PP, et al. Diagnostic terminology for reporting thyroid fine needle aspiration cytology: European Federation of Cytology Societies thyroid working party symposium, Lisbon 2009. Cytopathology 2010; 21: 86-89.
10. Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol 2009; 132(5): 658-665.
11. Cross PA, Chandra A, Giles T, Johnson S, Kocjan G, Poller D, Stephenson T. Guidance in the reporting of thyroid cytology specimens. Royal College of Pathologists, November 2009.
12. Fadda G, Basolo F, Bondi A, et al. Cytological classification of thyroid nodules: proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica 2010; 102: 405-408.
13. Gharib H, Papini E, Valcavi R, et al. AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12(1): 63-102.
14. Ali ZS, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. New York, Springer, 2010.
15. Dušková J. Nový systém pro sjednocené hodnocení tenkojehlových aspiračních biopsií štítné žlázy – Bethesda 2010. Cesk Patol 2011; 47(1): 8-14.
16. Dušková J. Nový systém mezinárodně sjednoceného hodnocení tenkojehlových aspiračních biopsií štítné žlázy: Bethesda klasifikace 2010. DMEV 2010; 13(4), 191-195.
17. Arola J, Kholová I, Timonen T, Krogerus L. Reporting of thyroid fine needle samples is changing in Finland--the Bethesda system in thyroid cytology. Duodecim 2010; 126(20): 2449-2453.
18. Cochand-Priollet B, Schmitt FC, Tötsch M, Vielh P. The Bethesda terminology for reporting thyroid cytopathology: from theory to practice in Europe. Acta Cytol 2011; 55(6): 507-511.
19. Cochand-Priollet B, Vielh P, Royer B, Belleannée G, Collet JF, Goubin-Versini I, Leteurtre E. Sous l’égide de la Société française de cytologie clinique. Ann Pathol 2012; 32(3): 177-183
20. British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer (Perros P, ed) 2nd edition. Report of the Thyroid Cancer Guidelines Update Group. London: Royal College of Physicians and MacMillan Cancer Support; 2007.
21. Pagni F, Prada M, Goffredo P, Isimbaldi G, Crippa S, Di Bella C, Leone BE. „Indeterminate for malignancy“ (Tir3/Thy3 in the Italian and British systems for clasification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact. Cytopathology 2014. In press.
22. Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer Cytopathol 2009; 117(3): 195-202.
23. Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S. Implications of the proposed thyroid fine-needle aspiration category of “follicular lesion of undetermined significance”: A five-year multi-institutional analysis. Diagn Cytopathol 2009; 37(10): 710-714.
24. Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC. The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 2009; 19(11): 1215-1223.
25. Shi Y, Ding X, Klein M, Sugrue C, Matano S, Edelman M, Wasserman P. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer Cytopathol 2009; 117(5): 298-304.
26. Hambleton C, Kandil E. Appropriate and accurate diagnosis of thyroid nodules: a review of thyroid fine-needle aspiration. Int J Clin Exp Med 2013; 6(6): 413-422.
27. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytologica 2012; 56: 333-339.
28. Walts AE, Bose S, Fan X, et al. A simplified Bethesda system for reporting thyroid cytopathology using only four categories improves intra- and inter-observer diagnostic agreement and provides non-overlapping estimates of malignancy risks. Diagn Cytopathology 2012; 40: E62-E68.
29. Singh RS, Wang HH. Eliminating the “atypia of undetermined significance/follicular lesion of undetermined significance” category from the Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2011; 136: 896-902.
30. Kurian EM, Dawlett M, Wang J, Gong Y, Guo M. The triage efficacy of fine needle aspiration biopsy for follicular variant of papillary thyroid carcinoma using the Bethesda reporting guidelines. Diagn Cytopathology 2012; 40 Suppl 1: E69-73.
31. VanderLaan PA, Krane JK, Cibas ES. Atypia of undetermined significance in thyroid fine-needle aspiration: characterizing cytopathologist practice patterns. Mod Pathol 2011; 24 (1 suppl): 107A.
32. Jing X, Knoepp SM, Roh MH et al. Group consensus review minimizes the diagnosis of “follicular lesion of undetermined significance” and improves cytohistologic concordance. Diagn Cytopathol 2012; 40(12): 1037-1042.
33. VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol 2011; 136(4): 572-577.
34. Renshaw AA. Should “atypical follicular cells” in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol 2010; 118: 186-189.
35. Önder S, Firat P, Ates D. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate cytegories. Cytopathology 2014; 25(3); 177-184.
36. Walts AE, Mirocha J, Bose S. Follicular lesion of undetermined significance in thyroid FNA revisited. Diagn Cytopathol 2014; 42(1): 18-22.
37. Yazgan A, Balci S, Dincer N, et al. Hurthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology. Cytopathology 2014; 25(3); 185-189.
38. Smith M, Pantanowitz L, Khalbuss WE, Benkovich VA, Monaco SE. Indeterminate pediatric thyroid fine needle aspirations: a study of 68 cases. Acta Cytol 2013; 57: 341-348.
39. Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2010; 134(3): 450-456.
40. Somma J, Schlecht NF, Fink D, Khader SN, Smith RV, Cajigas A. Thyroid fine needle aspiration cytology: follicular lesions and the gray zone. Acta Cytol 2010; 54(2): 123-131.
41. Marchevsky AM, Walts AE, Bose S, et al. Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol 2010; 38(4): 252-259.
42. VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated FNA be the preferred initial approach? Am J Clin Pathol 2011; 135(5): 770-775.
43. Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF V600E mutation status. J Clin Endocrinol Metab 2011; 96: 658-664.
44. Mondal SK, Sinha S, Basak B, Roy DN, Sinha SK. The Bethesda system for reporting ttyroid fine needle aspirates: A cytologic study with histologic follow-up. J Cytol 2013; 30(2): 94-99.
45. Absher KJ, Truong LD, Khurana KK, Ramzy I. Parathyroid cytology: avoiding diagnostic pitfalls. Head Neck 2002; 24: 157-164.
46. Bhanot P, Yang J, Schnadig VJ, et al. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinom: report of six cases and review of the literature. Diagn Cytopathol 2007; 35: 285-292.
47. Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008; 9: 543-549.
48. Kholová I, Ryška A, Ludvíková M, Čáp J, Pecen L. Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 2003; 14(1): 27-31.
49. VanderLaan PA, Marqusee E, Krane JF. Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. Cancer Cytopathol 2012; 120(4): 245-253.
50. Kleiman DA, Beninato T, Soni A, Shou Y, Zarnegar R, Fahey TJ. Does Bethesda Category Predict Aggressive Features in Malignant Thyroid Nodules? Ann Surg Oncol 2013; 20(11): 3484-3490.
51. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94(6): 2092-2098.
52. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013; 98(11): E 1852-1860.
53. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381(9871): 1058-1069.
54. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012; 367(8): 705-715.
55. Ali SZ, Fish SA, Lanman R, Randolph GW, Sosa JA. Use of the afirma® gene expression classifier for preoperative identification of benign thyroid nodules with indeterminate fine needle aspiration cytopathology. PLoS Curr. In press 2013.
56. Hodak SP, Rosenthal DS. American Thyroid Association Clinical Affairs Committee. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid 2013; 23(2): 131-134.
57. Na DG, Kim J, Sung JY, Baek JH, Jung KC, Lee H, Yoo H. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid 2012; 22(5): 468-474.
58. Hakala T, Kholova I, Sand J, Saaristo R, Kellokumpu-Lehtinen P. A core needle biopsy provides more malignancy-specific results than fine-needle aspiration biopsy in thyroid nodules suspicious for malignancy. J Clin Pathol 2013; 66(12): 1046-1050.
59. Hahn SY, Shin JH, Han BK, Ko EY, Ko ES. Ultrasonography-guided core needle biopsy for the thyroid nodule: does the procedure hold any benefit for the diagnosis when fine-needle aspiration cytology analysis shows inconclusive results? Br J Radiol 2013; 86(1025): 20130007.
Štítky
Anatomical pathology Forensic medical examiner ToxicologyČlánok vyšiel v časopise
Czecho-Slovak Pathology
2014 Číslo 3
Najčítanejšie v tomto čísle
- Intestinal metaplasia of the stomach and esophagus: an immunohistochemical study of 60 cases including comparison with normal and inflamed intestinal mucosa
- Soft tissue tumors - the view of the molecular biologist
- Up-to-date experience with the international classification system Bethesda 2010 for thyroid fine-needle aspirate: a review
- A complex diagnostic approach in lymphomas: practical aspect in short case reports